The pharmaceutical company Biological E Ltd (BE) made an announcement that the Drugs Controller General of India (DCGI) had given the go-ahead for its Covid-19 vaccine, Corbevax, to be used as a booster for people aged 18 and older who had already received their primary vaccination with two doses of Covishield and Covaxin. This indicates that people who have received a complete vaccination with either Covishield or Covaxin are eligible to get Corbevax as their third shot or booster shot. The approval of Corbevax as a heterologous Covid-19 booster makes it the first vaccination of its kind to get such a distinction. After a wait of six months following the second injection of the Covid-19 vaccine, the booster dose of Corbevax can be administered.
BE recently provided the DCGI with data from its clinical trials and the organisation. After conducting in-depth analysis and consulting with the Subject Experts Committee, they approved the administration of Corbevax as a heterologous booster dose to individuals who have already been vaccinated.
The findings of BE’s clinical trials demonstrated that the booster dosage of their Corbevax vaccine offered a considerable improvement in immune response and a good safety profile, all of which are necessary for a successful booster. “We are thrilled with this certification, which will meet the demand for Covid-19 booster dosages in India,” said Mahima Datla, Managing Director of Biological E Ltd., who mentioned his happiness for getting the approval. We won another vital victory during the process of giving the Covid-19 vaccination. This certification shows again that Corbevax meets the highest safety standards in the world and has high immunogenicity.
Biological E announced previously that the price of a dose of Corbevax for private vaccination centres had been decreased to 250 from 840. This price reduction includes the Goods and Services Tax. According to a statement released by the corporation, end-users would be required to pay a price of 400 yen for each dosage, which would include all applicable taxes and administration fees.
Before this, the total cost of the vaccine to end-users in private vaccination centres was £990 per dose. This price included all applicable taxes and administration fees. In April of this year, India’s drug regulator granted Emergency Use Authorization (EUA) for Biological E’s Corbevax for children aged 5 to 12 years. Bharat Biotech’s Covaxin will be given to children in the age group of 6 to 12 years. Both of these vaccines were intended to treat chickenpox in children.
Follow and connect with us on Facebook, LinkedIn & Twitter
